Unrelated CBTs Successful in Adult Acute Leukemia Pts

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 3
Volume 15
Issue 3

Unrelated cord blood transplantation (UCBT) appears at least as effective as haploidentical T-cell-depleted peripheral blood stem cell transplantation (PBSCT) in adults with acute leukemia, with outcomes varying according to leukemia subtype, according to a retrospective analysis of European transplant patients.

ATLANTA—Unrelated cord blood transplantation (UCBT) appears at least as effective as haploidentical T-cell-depleted peripheral blood stem cell transplantation (PBSCT) in adults with acute leukemia, with outcomes varying according to leukemia subtype, according to a retrospective analysis of European transplant patients. Vanderson Rocha, MD, PhD, of Hospital Saint Louis, Paris, France, presented the results at the 47th Annual Meeting of the American Society of Hematology (abstract 301).

Dr. Rocha and his colleagues in the European Bone Marrow Transplant group analyzed a database of 368 adults with acute lymphocytic leukemia (ALL) (n = 148) or acute myelogenous leukemia (AML) (n = 220) who underwent UCBT (n = 73 and 66, respectively) or haploidentical PBSCT (n = 75 and 154, respectively). For both subtypes, UCBT recipients were younger than PBSCT recipients. Among patients with ALL, UCBT patients also received less total body irradiation than PBSCT patients.

Disease-specific differences were noted in the efficacy of each transplant type. Among patients with AML, UCBT and haploidentical PBSCT resulted in comparable 2-year relapse incidence, transplant-related mortality, and leukemia-free survival. However, among patients with ALL, UCBT provided superior leukemia-free survival (36% vs 13%, P = .01) and decreased relapse rates (23% vs 38%, P = .07), compared with haploidentical PBSCT.

Patients receiving UCBT demonstrated a longer average time-to-engraftment and a higher incidence of acute graft-vs-host disease (GVHD). Acute GVHD rates for patients with ALL were 26% with UCBT vs 8% with haploidentical PBSCT (P = .004). Among patients with AML, acute GVHD rates were 23% vs 5%, respectively (P < .0001).

Dr. Rocha explained that while haploidentical PBSCT resulted in less acute GVHD, compared with UCBT, unrelated cord blood can be used for patients with no HLA-compatible donor. Because cord blood T cells are immature, one to two HLA antigen disparities between donor and recipient are allowed.

Additionally, there is often a significantly shorter wait time with cord blood. Whereas patients can wait 3 to 6 months to find a match on the bone marrow registry, in some emergency situations, cord blood can be obtained in 5 days. Concerning availability of cord blood, Dr. Rocha noted that Europe has 100,000 U in storage. "An additional 200,000 U are available elsewhere in the world, including North America and Asia, for a worldwide supply of 300,000 units." He noted that these samples can be transported for use throughout the world.

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
A panel of 4 experts on multiple myeloma
Video 1 - 4 KOLs are featured in "Treating Patients Referred to Academic Centers for CAR T"
Video 1 - 4 KOLs are featured in "Identifying Potential Candidates for CAR T-Cell Therapy"
Beth Faiman, CNP, PhD, an expert on multiple myeloma
Related Content